Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic disorders in reducing severe aGVHD.
Acute graft-versus-host disease (aGVHD) is a major complication and leading cause of non-relapse mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Preliminary research findings suggest that the addition of CD25 monoclonal antibody at +3 days post unrelated umbilical cord blood transplantation (UCBT) has reduced the incidence of grade III-IV aGVHD compared to previous protocols. In order to further explore how to improve prevention strategies of aGVHD and reduce the incidence of severe aGVHD, we performed this study to evaluate the safety and effectiveness of a prophylactic GVHD regimen utilizing CD25 monoclonal antibody post-UCBT for malignant hematologic disorders, aimed at reducing the incidence of severe aGVHD.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| basiliximab group | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Basiliximab | Drug | Addition of CD25 monoclonal antibody（Basiliximab） at +3 days post unrelated umbilical cord blood transplantation (UCBT) |
|
| Measure | Description | Time Frame |
|---|---|---|
| The cumulative incidence of grade III-IV acute graft-versus-host disease (aGVHD) | The primary endpoint of the study will be the development of aGVHD in the first 100 days post-transplant. Acute GVHD was graded according to the International Consortium criteria. | within 100 days post-UCBT |
| Measure | Description | Time Frame |
|---|---|---|
| The incidence rate and occurrence time of pre-engraftment syndrome (PES) | The occurrence time and cumulative incidence of PES within 30 days post-UCBT. The PES was diagnosed according to the criteria of engraftment syndrome (ES) . | within 30 days post-UCBT |
| The cumulative incidence of neutrophil engraftment at 28 days after transplantation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Xiaoyu Zhu, Ph.D | Contact | 15255456091 | xiaoyuz@ustc.edu.cn | |
| Kaidi Song, M.D | Contact | 18715062778 | kaidisong@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Xiaoyu Zhu, Ph.D | The First Affiliated Hospital of USTC (Anhui Provincial Hospital) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) | Hefei | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Addition of CD25 monoclonal antibody at +3 days post unrelated umbilical cord blood transplantation (UCBT)
Not provided
Not provided
Not provided
Not provided
Neutrophil engraftment time was defined as the first of three consecutive days during which the neutrophil count was at least 0.5×10^9/L. |
| within 28 days post-UCBT |
| The cumulative incidence of platelet engraftment at 100 days after transplantation | Platelet engraftment is defined as independence from platelet transfusion for at least 7 days with a platelet count of more than ≥ 20 × 10^9/L. | within 100 days post-UCBT |
| The incidence of grade II to IV aGVHD | The cumulative incidence of grade II to IV aGVHD in the first 100 days post-transplant. aGVHD was graded according to the aGVHD International Consortium criteria. | within 100 days post-UCBT |
| The cumulative incidence of chronic GVHD at 360 days after transplantation | The severity of chronic GVHD was graded according to the 2014 NIH criteria. | 360 days |
| The cumulative incidence of transplant-related mortality at 180 days after transplantation | The cumulative incidence of transplant-related mortality at 180 days after transplantation. | 180 days |
| The cumulative incidence of relapse | The cumulative incidence of relapse at 1 year after transplantation. | 1 year |
| The probability of disease-free survival(DFS) | The DFS was defined as the interval between transplantation and disease recurrence, death or the last follow-up date, whichever occurred first. | 1 year |
| The probability of overall survival(OS) | The OS was determined to be the time from the first day of transplantation until death from any cause or the last follow-up date. | 1 year |
| The probability of GVHD-free, relapse-free survival(GRFS) | The composite endpoint of GRFS was defined as the first events occurring after transplantation among Grade III to IV aGVHD, moderate to severe cGVHD, relapse, or death for any reason. | 1 year |
| ID | Term |
|---|---|
| D019337 | Hematologic Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077552 | Basiliximab |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided